Stratified Medicine of Eplerenone in Acute MI/Injury (StratMed-MINOCA)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05198791 |
|
Recruitment Status :
Recruiting
First Posted : January 20, 2022
Last Update Posted : April 25, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Patients with heart attack or heart injury are tested (angiogram) for blockages in their arteries. Many patients develop heart problems caused by damage to small (microvascular) blood vessels. These issues are also relevant to patients with coronarvirus-19 disease (COVID-19). Eplerenone reduces blood vessel injury and is used to treat heart failure.
Aim: to test the use of eplerenone in patients with heart attack/heart injury who have small vessel disease, including patients with COVID-19
Patients referred to the Golden Jubilee hospital with a suspected heart attack heart / injury will be invited to participate into a registry-based clinical trial. Screening, enrolment and verbal, informed consent will be obtained during the angiogram then written consent on the ward. Small vessel disease will be assessed using a 'diagnostic' guidewire during the standard angiogram. People with small vessel problems will be allocated to a clinical trial of usual care or eplerenone. Coronary microvascular dysfunction is defined as an index of microvascular resistance ≥25. Coronary flow reserve (CFR abnormal <2.0) and resistance reserve ratio (RRR abnormal <2.0), measured simultaneously with IMR, are predefined parameters of interest.
Patients will be allocated into one of the 3 groups:
- Group 1: Patients without coronary microvascular dysfunction. No eplerenone
- Group 2: Patient with coronary microvascular dysfunction. Usual care, no eplerenone.
- Group 3: Small vessels abnormal. Eplerenone tablets.
The primary outcome for the trial will be reduced heart injury (biomarkers) in patients with microvascular disease. We will also test heart function (MRI scan) at enrolment and at six months. All patients (Groups 1, 2 and 3) will have an angiogram. Standard blood tests will be collected during the hospital stay, and then again at 1 and 6 months. Other outcomes include questionnaires (health status). We will gather information on longer-term health outcomes (hospitalisation, death) using confidential electronic record linkage. We will ask for permission to store blood samples for future research.
The research will improve scientific knowledge about eplerenone therapy in this patient group. The study will create a repository of clinical samples and images which will provide vital data for studies of COVID-19.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Myocardial Infarction, Acute Myocardial Infarction With Nonobstructive Coronary Arteries Myocardial Injury | Drug: Stratified medicine - Microvascular dysfunction and eplerenone therapy, tablets Other: Stratification and standard care | Phase 2 |
Background: Myocardial infarction with non-obstructive coronary arteries (MINOCA) involves vascular dysfunction, prognosis is impaired and specific treatments are lacking. Mineralocorticoid antagonist (MRA) therapy attenuates left ventricular remodelling in patients with acute MI without heart failure e.g. REMINDER trial.
Stratified medicine is defined by the Medical Research Council Framework (2015) as the identification of key sub-groups of patients within a heterogeneous population; these being distinguishable groups with differing mechanisms of disease, or particular responses to treatments. Stratification can be used to improve mechanistic understanding of disease processes and enable: the identification of new targets for treatments; the development of biomarkers for disease risk, diagnosis, progression and response to treatment; and treatments to be tested and applied in the most appropriate patient groups.
Objective: To implement stratified medicine in MINOCA.
Hypothesis: In MINOCA, early risk stratification by coronary microvascular dysfunction (index of microvascular resistance (IMR) ≥25) coupled with cardio-protective MRA therapy using eplerenone limits myocardial damage reflected by changes in N-terminal (NT)-pro hormone BNP (NT-proBNP).
Aim: To undertake a developmental clinical study, clarify evidence-gaps and provide training in academic cardiology. Prospective randomized open, blinded end-point (PROBE) design: Step-1: Screening in during coronary angiography of patients with acute myocardial infarction including MINOCA without heart failure or left ventricular ejection fraction ≤40%; Step-2: Guidewire-based measurement of microvascular resistance (culprit artery or if unknown, the left anterior descending coronary artery. Registry population, n=300); Step-3: Stratify subgroup with -increased vascular risk (IMR≥25) (Trial, n=150 eligible for MRA, informed consent); Step-4: Randomise this higher-risk group: eplerenone 25-50 mg daily for 6 months or standard care. Coronary physiology parameters including coronary flow reserve (CFR abnormal <2.0), the resistance reserve ratio (RRR abnormal <2.0) and left ventricular end-diastolic pressure will be prospectively measured.
Outcomes: Primary: within-subject change in NT-proBNP by group; Secondary: left ventricular ejection fraction; left ventricular volumes; patient reported outcome measures (PROMS). Value: Evidence-synthesis on stratified medicine for MINOCA.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 350 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Prospective, randomised, open-label, blinded, end-point (mechanistic, PROBE design). |
| Masking: | Double (Participant, Outcomes Assessor) |
| Masking Description: | Participants will be masked on their assignment to either the control group vs. registry. Assessors for the primary outcome (laboratory measurement) will be blinded to treatment group assigment. |
| Primary Purpose: | Treatment |
| Official Title: | The Effect of Mineralocorticoid Receptor Antagonist Therapy in Patients With Acute Myocardial Infection or Injury and Cardiovascular Risk Factors: a Registry-based, Stratified-medicine, Randomised, Controlled Trial |
| Actual Study Start Date : | February 4, 2022 |
| Estimated Primary Completion Date : | July 31, 2026 |
| Estimated Study Completion Date : | July 31, 2026 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Eplerenone
Patients with MINOCA and an index of microvascular resistance (IMR) greater than or equal to 25 will be randomised to receive eplerenone (starting dose 25 mg, uptitrated to 50mg after two weeks) for six months or standard of care and research protocol study visits. Patients who are screened, give informed consent but are not randomized will enter a followup registry.
|
Drug: Stratified medicine - Microvascular dysfunction and eplerenone therapy, tablets
Stratified medicine including interventional diagnostic procedure (IDP) and linked treatment with eplerenone. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months.
Other Name: Eplerenone |
|
Sham Comparator: Standard of care
Patients with MINOCA and an index of microvascular resistance (IMR) greater than or equal to 25 will be randomised to receive eplerenone (starting dose 25 mg, uptitrated to 50 mg after two weeks) for six months or standard of care and research protocol study visits. Patients who are screened, give informed consent but are not randomized will enter a followup registry.
|
Other: Stratification and standard care
Interventional diagnostic procedure (IDP) without linked treatment i.e., standard care. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. In the standard care group, the IDP is performed but the results are not disclosed. The IDP is therefore a sham procedure. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months. |
- Within patient change in NTproBNP [ Time Frame: Enrolment, thirty days and six months ]NTproBNP will be measured at enrolment, thirty days and six months
- Biomarkers of vascular inflammation [ Time Frame: Enrolment, thirty days and six months ]Vascular cell adhesion molecule (VCAM) is a biological marker of vascular inflammation. VCAM will be measured at enrolment, thirty days and six months
- Myocardial blood flow at 6 months (MRI) [ Time Frame: Performed at six months ]Cardiac MRI with adenosine stress perfusion to measure myocardial blood flow
- Health-related quality of life, patient-assessed [ Time Frame: Enrolment, thirty days and six months ]European Quality of Life 5-domain 5-Level (EQ-5D-5L) questionnaire, a patient reported outcome measure. Patient assessed score - Scale 0 (worst), 100 (best)
- Left ventricular remodelling at 6 months (MRI) [ Time Frame: Within fourteen days of enrolment and at six months ]Cardiac MRI performed within fourteen days of enrolment and at six months
- Health economics [ Time Frame: Enrolment, thirty days and six months ]Institute for Medical Technology Assessment Productivity Cost Questionnaire (iPCQ)
- Fibrosis [ Time Frame: Enrolment, thirty days and six months ]Circulating (plasma) concentration of procollagen type-I C-terminal pro-peptide (PICP) and collagen type-1 C-terminal telopeptide (CITP) reflect synthesis and degradation of type-I collagen and PICP/CITP ratio reflects collagen turnover.
- Haemostasis pathway activation [ Time Frame: Enrolment, thirty days and six months ]Circulating (plasma) concentration of factor VIII and other biomarkers of haemostasis pathway activation e.g. D-dimers, fibrinogen
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥18 years.
- Acute myocardial infarction or myocardial injury and no obstructive coronary arteries.
- Cardiovascular risk factor (≥1): age >70 years, atrial fibrillation, diabetes, current smoker, eGFR 30 - 60 mL/ minute/1.73 m2, prior MI, treated hypertension or COVID-19 (confirmed or suspected)
- Coronary angiography.
Exclusion Criteria (trial):
- Obstructive coronary artery disease
- Left ventricular ejection fraction ≤40% with evidence of heart failure, following myocardial infarction.
- Estimated glomerular filtration rate <30 mL/ minute/1.73 m2
- Severe liver impairment
- Women who are pregnant, breast-feeding or of child-bearing potential (WoCBP) without a negative pregnancy test and who are unwilling or unable to follow the reproductive restrictions defined in the eligibility criteria and use highly effective contraception as defined in Appendix 2 for the duration of the study treatment and 30 days after last dose of study drug.
- Patients taking one of the following medicines :
- Pre-existing treatment with an MRA :
- Anti-fungal drugs (ketoconazole or itraconazole).
- Antiviral medication (nelfinavir or ritonavir).
- Antibiotics (clarithromycin or telithromycin).
- Nefazodone used to treat depression.
- The combination of an angiotensin converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB)) together.
Exclusion Criteria (registry):
- Contra-indication to cardiovascular magnetic resonance imaging e.g. severe claustrophobia, metallic foreign body.
- Contra-indication to intravenous adenosine, i.e. severe asthma; long QT syndrome; second- or third-degree atrio-ventricular block and sick sinus syndrome.
- Lack of informed consent.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05198791
| Contact: Colin Berry, PhD | 01413303325 | colin.berry@glasgow.ac.uk |
| United Kingdom | |
| Golden Jubilee National Hospital | Recruiting |
| Glasgow, United Kingdom | |
| Contact: Colin Berry, PhD 01419515000 colin.berry@glasgow.ac.uk | |
| Sub-Investigator: Robert A Sykes, MBChB | |
| Principal Investigator: Colin Berry, PhD | |
| Principal Investigator: | Colin Berry, PhD | University of Glasgow |
| Responsible Party: | Colin Berry, Professor, NHS National Waiting Times Centre Board |
| ClinicalTrials.gov Identifier: | NCT05198791 |
| Other Study ID Numbers: |
StratMed-MINOCA |
| First Posted: | January 20, 2022 Key Record Dates |
| Last Update Posted: | April 25, 2022 |
| Last Verified: | April 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Data will be shared based on a bon fide research request and sponsor approval. |
| Supporting Materials: |
Study Protocol Informed Consent Form (ICF) Clinical Study Report (CSR) |
| Time Frame: | At the end of the study |
| Access Criteria: | Bon fide research request and sponsor approval. |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
|
Stratified Medicine Mineralocorticoid receptor antagonists MINOCA |
Myocardial injury Myocardial infarction Myocardial Infarction with Nonobstructive Coronary Arteries |
|
Myocardial Infarction MINOCA Infarction Wounds and Injuries Ischemia Pathologic Processes Necrosis Myocardial Ischemia Heart Diseases Cardiovascular Diseases |
Vascular Diseases Eplerenone Mineralocorticoid Receptor Antagonists Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Diuretics, Potassium Sparing Diuretics Natriuretic Agents Antihypertensive Agents |